



Highlights on Unique Orange Pore Cap Mushroom *Favolaschia* Sp. and Beech Orange Mushroom *Cyttaria* sp. and Their Biological Activities

Elkhateeb WA* and Daba GM

Chemistry of Natural and Microbial Products Department, Pharmaceutical Industries Researches Division, National Research Centre, Egypt

*Corresponding author: Waill A Elkhateeb, Chemistry of Natural and Microbial Products Department, Pharmaceutical Industries Researches Division, National Research Centre, El Buhouth St., Dokki, 12311, Giza, Egypt, Email: waillahmed@yahoo.com

Review Article

Volume 5 Issue 3

Received Date: July 15, 2021

Published Date: August 13, 2021

DOI: 10.23880/oajpr-16000246

Abstract

Fungi exist everywhere around us. However, edible Mushrooms represent promising source for novel compounds with potential uses in different biotechnological fields. Many mushrooms were sources of novel compounds showing biological actions such as antimicrobial, anticancer, antiinflammatory activities. Likewise, mushrooms are macrofungi that exist everywhere around us. They have significant roles in human life as source of nutrition and bioactive compounds. Many mushrooms have been reported as promising biotechnological tools for production of secondary metabolites of various biological activities. *Favolaschia* sp.; *Cyttaria* sp. mushrooms are especially interesting due to the rareness of Basidiomycetes. In this review, the ecology, occurrence, of unique *Favolaschia* sp.; *Cyttaria* sp. mushrooms were described, and their biological activities.

Keywords: Medicinal Mushrooms; *Favolaschia* sp.; *Cyttaria* sp.; Biological Activities

Introduction

Mushroom producing fungi belong to Basidiomycetes and Ascomycetes, including edible and non-edible species, and some mushroom fruiting body produces basidiospores at the tip of club like structures called basidia, which are arranged along the gills of the mushroom [1-5]. Mushrooms have been documented for centuries as use as food and medicine as they are generous sources of nutrients and biologically active compounds that have various applications in agriculture, food, pharmaceuticals, cosmetics, and food related industries, amongst others [6-10].

Mushroom obtain their nutrition through being saprotrophs, parasites, or symbionts such as mycorrhiza. Mushrooms are the reproductive phase (fruiting bodies) but they there is also a vegetative phase to these fungi (mycelia).

Edible mushrooms are often low in calories and can be healthy sources of proteins, flavonoids, metals, amino acids, minerals, volatile oils, carotenoids fats, phenolic compounds, and different vitamins and ergosterol that can be used as a source for vitamin D2 [3,5,11-18].

The diversity of compounds extracted from mushrooms has attracted attention as a mine for novel compounds. Some compounds they contain have been classified as Host Defence Potentiators (HDP) which can have immune system enhancement properties [103, 105]. Various compounds are responsible for different therapeutic activities of many mushrooms genera. Various biological activities have been reported such as anticancer, antiinflammatory, hypoglycemic, antimicrobial, antioxidant, immunomodulatory, antiviral, hepatoprotective, antineurodegenerative, antiangiogenic, and hypocholesterolemic activities [19-28].

Favolaschia sp.

Favolaschia sp. belonging to Basidiomycota; Class: Agaricomycetes; Order: Agaricales; Family: *Mycenaceae*. *Favolaschia* sp., commonly known as the orange pore fungus, is a species of fungus in the family *Mycenaceae*. Due to its form it is also known as orange pore conch or orange Ping-Pong bat. Throughout much of its expanded range *Favolaschia calocera* is now considered an invasive species. It colonizes ruderal sites along transport routes and can become main in habitats disturbed by human activity. *Favolaschia calocera* is a wood-inhabiting saprotrophic fungus. It often has a bright yellow color at first, and can later appear in a brownish yellow color, though it often presents as a bright orange stalked fan, 5 mm–30 mm diameter, with prominent

pores on the underside. Fruit-body: This little fungus is very bright orange in colour. It is fan shaped like a ping pong bat, with a short stem (up to 20 mm long), attached to the side of the cap and to logs or dead branches. Instead of gills it has large pores giving it a honeycombed appearance. The pore openings are polygonal to elliptical with a finely hairy inner surface. There are generally 1–2 pores per mm but they are smaller and shallower near the margin. The stem is rudimentary, about 5mm long, with sparse short white hairs and laterally attached [29-32]. The pores are visible through the thin flesh. Spore print: White. Habit: Although not common in gardens. It grows in large troops on logs and is very visible in the rainforest (Figures 1 and 2).



Figure 1: *Favolaschia calocera*, (Photo was taken by: Mikey Watson. Locality: New Zealand, Auckland, Rhinevale close Henderson Auckland (Cited in: <https://mycoportal.org>).




Figure 2: *Favolaschia* Sp, (Photo was taken by: John B. Locality: New Zealand, Nelson, 14 Rocklands Rd, Clifton (Cited in: <https://mycoportal.org>).

Favolaschia Sp. Biological Activities

Kornsakulkarn, et al. reported that fourteen new compounds, oudemansins, oudemansinols, favolasins, favolasinin, polyketides, and (R,E)-2,4-dimethyl-5-phenyl-4-pentene-2,3-diol, together with nine known compounds

were isolated from the basidiomycete fungus *Favolaschia* sp. BCC 18686 [33]. Two new compounds, favolasin E and 9-oxostrobilurin E, were isolated from *Favolaschia calocera* BCC 36684 along with nine β -methoxyacrylate-type derivatives. Compounds in the class of oudemansins and strobilurins exhibited moderate to strong antimalarial

activity with relatively low cytotoxicity against Vero cells. Potent antimalarial activity was demonstrated for 9-methoxystrobilurins G, K, and E. Also, several compounds showed specific cytotoxicity against NCI-187 cells (human small-cell lung cancer).

Two strobilurins, 9-methoxystrobilurin B and 9-methoxystrobilurin G, two monochlorinated 2,3-dihydro-1-benzoxepin derivatives, and butenolide, together with four known compounds, strobilurin B, 9-methoxystrobilurin A, and oudemansins A and B, were isolated from culture BCC 18689 of the fungus *Favolaschia* sp. 9-Methoxystrobilurins A, B, and G and oudemansins A and B exhibited antimalarial, antifungal, and cytotoxic activities [34]. Wood, et al. Submerged liquid cultures of the basidiomycete *Favolaschia pustulosa* afforded the novel 9-methoxystrobilurin derivatives, 9-methoxystrobilurin L and 9-methoxystrobilurin E, and the related oudemansin derivative, oudemansin L [35]. 9-methoxystrobilurin L was cytotoxic to cells of the human B lymphoblastoid cell line (Jijoye), with an IC50 of 1.8 nM. This cytotoxicity was observed in a 5-day assay only and was not apparent after 2 days. 9-methoxystrobilurin L showed some antibacterial activity against *Bacillus subtilis* and antifungal activity against *Candida albicans*.

Favolaschia sp. 87129, *Pterula* sp. 82168, *Collybia nivalis* and *Omphalotus olearius* were cultivated on natural substrates. The antibiotic metabolites oudemansin A, strobilurins A, D, illudin S and pterulone were isolated and identified. A new antifungal metabolite, pterulone B, was described from cultures of *Pterula* sp. 82168 on wood. *Collybia nivalis* was found to be the first species of this genus to produce strobilurins and oudemansin A. The concentrations of the antibiotics, however, were sufficient to inhibit other saprophytic fungi [36]. Favolon triterpenoid from a *Favolaschia* species exhibits potent antifungal activity but does not show cytotoxic activity on L 1210 cells [37]. Laschiatrion, a new antifungal antibiotic, was isolated from fermentations of *Favolaschia* sp. 87129. Laschiatrion exhibits

broad in vitro activity against several human pathogens while no antibacterial and cytotoxic activities could be detected. The structure was elucidated by spectroscopic techniques [38].

Cyttaria Sp.

Cyttaria sp., commonly known as the myrtle orange or beech orange, is an orange-white coloured and edible ascomycete fungus native to Australia. It is a specific parasite of myrtle beech (*Nothofagus cunninghamii*) trees. *Cyttaria gunnii* is an ascomycete in Class: Leotiomycetes; Order: Cyttariales; Family Cyttariaceae. It is a caulicolous (stem parasite) fungi, restricted to species of *Nothofagus*, specifically *Nothofagus cunninghamii*, *Nothofagus fusca*, and *Nothofagus menziesii*. The species is distributed throughout Australia, New Zealand, and Tasmania wherever host trees are also found. The fruiting bodies, which grow in clusters, are usually around 2cm in diameter. The yellow/orange cup-shaped cavities form upon maturity to release wind-dispersed spores.

Stromata solitary or in dense clusters, up to 2 cm in diameter, pear-shaped, smooth and dry but becoming slimy if wetted, fawn or tan above, light coloured below, bright yellow when mature except for a sterile base which remains white. Hollow at maturity, internal fibres white. Apothecia very numerous, up to 200, bright yellow. Papillae small, scattered between apothecia, appearing as white flecks on young stroma, arising as minute elevations within shallow depressions, not raised above the surface of the stroma. Pycnidia absent. Asci 145-165 x 14 µm, ascospores sub-globose 12-12.5 x 6.5-12 µm, dark coloured, and spore print black. Paraphyses as long as asci, 2 µm wide, septate, branched, swollen at ends. Habitat: An obligate parasite forming globose galls on *Nothofagus menziesii* (Hook f.) Oerst, in New Zealand and *Nothofagus cunninghamii* (Hook. f.) Oerst, in Tasmania and Victoria. Range in New Zealand as for host (Figures 3&4) [39,40].



Figure 3: *Cyttaria gunnii*, (Photo was taken by: Kristof Zyskowski. Locality: Australia, Tasmania, Mount Field National Park, National Park, Tasmania, Australia (Cited in: <https://mycoportal.org>).



Figure 4: *Cyttaria* Sp. (Photo was taken by Tng, D. Locality: Australia, (Cited in: <https://mycoportal.org>).

***Cyttaria* sp. Biological Activities**

The antioxidant capacities of the methanolic extracts of the dried caps of *Cyttaria gunnii* was determined using a number of different chemical reactions in evaluating multi-mechanistic antioxidant activities. These included the Trolox equivalent antioxidant capacity, ferric ion reducing antioxidant power, and ferrous ion chelating activity. Mineral contents of the dried caps of the mushroom was also determined by inductively coupled plasma–optical emission spectroscopy. The results indicated that *Cyttaria gunnii* edible wild mushrooms have a high antioxidant capacity. It can be concluded that *Cyttaria gunnii* edible wild mushroom are good source of nutritional antioxidants and a number of mineral elements [41].

Chemical and bioactive properties of nine wild edible mushrooms from native *Nothofagus* forest from Patagonia, Argentina. Macronutrients, sugars, fatty acids, tocopherols, organic acids, phenolic compounds and antioxidant properties were determined by Toledo, et al. [42]. Protein was found in high levels *Cyttaria hariotii*. All of them presented mannitol and trehalose as main sugars. The major fatty acid found was linoleic acid, followed by oleic acid and palmitic acid. All species presented oxalic and fumaric acids, while some also had malic, quinic and citric acids. Tocopherols composition was variable. All presented the best results in antioxidant activity assay, the highest content of phenolic compounds presenting gallic, p-hydroxybenzoic, p-coumaric and cinnamic acids.

The edible mushroom *Cyttaria espinosae* is a valuable food resource, not only because its pleasant taste, but also for its nutritional properties. Leiva-Portilla, et al. studied the physicochemical characterization and antioxidant capacity determination of dehydrated *Cyttaria espinosae* [43]. The results show that this wild mushroom is a good source of β -carotene, proteins and nutritionally relevant minerals, especially K and Fe. Also, dehydration of *Cyttaria espinosae*

by freeze-drying gives the possibility of adding value to this mushroom, due to the bioactive compounds are maintained, the structure were less collapsed and fewer changes occurred with respect to color and appearance when comparing with hot air-dried samples. And finally show that drying technologies will help to expand the market for this valuable resource and poses the challenge of working for a better management and conservation of related habitats [43,44].

Conclusion

Mushrooms are generous sources of numerous secondary metabolites showing various biological activities of great importance in different field, especially in the field of pharmaceutical industries. This review represents chemical composition and nutritional value of most of *Favolaschia* sp. and *Cyttaria* sp. Furthermore, it provides important information necessary to characterize and define the use of these species as, functional foods and sources of bioactive compounds. Moreover, such rarely isolated mushrooms can represent unique sources for novel metabolites that may contribute in treatment of currently untreated diseases or have other promising applications that help in serving humanity.

References

1. Elkhateeb WA, Daba GM, Thomas PW, Wen TC (2019) Medicinal mushrooms as a new source of natural therapeutic bioactive compounds. *Egypt Pharmaceu J* 18(2): 88-101.
2. Elkhateeb WA, Daba GM, Elnahas M, Thomas P, Emam M (2020) Metabolic profile and skin-related bioactivities of *Ceriporus squamosus* hydromethanolic extract. *Biodiversitas J Biological Div* 21(10).
3. Elkhateeb WA, Daba G (2020) Review: The endless nutritional and pharmaceutical benefits of the Himalayan gold, *Cordyceps*; Current knowledge and

- prospective potentials. *Biofarmasi Journal of Natural Product Biochemistry* 18(2): 70-77.
4. Elkhateeb WA, Daba GM (2020) *Termitomyces Marvel Medicinal Mushroom Having a Unique Life Cycle*. *Open Access Journal of Pharmaceutical Research* 4(1): 1-4.
 5. Daba GM, Elkhateeb W, ELDien AN, Fadl E, Elhagrasi A, et al. (2020) Therapeutic potentials of n-hexane extracts of the three medicinal mushrooms regarding their anti-colon cancer, antioxidant, and hypocholesterolemic capabilities. *Biodiversitas* 21(6): 2437-2445.
 6. Elkhateeb WA (2020) What medicinal mushroom can do?. *Chem Res J* 5(1): 106-118.
 7. Elkhateeb WA, Daba GM, Elmahdy EM, Thomas PW, Wen TC, et al. (2019) Antiviral potential of mushrooms in the light of their biological active compounds. *ARC J Pharm Sci* 5(2): 45-49.
 8. El-Hagrassi A (2020) In vitro bioactive potential and chemical analysis of the n-hexane extract of the medicinal mushroom, *Cordyceps militaris*. *Malays J Microbiol* 16(1): 40-48.
 9. Elkhateeb WA, Daba GM, El-Dein AN, Sheir DH, Fayad W, et al. (2020) Insights into the in-vitro hypocholesterolemic, antioxidant, antirotavirus, and anticolon cancer activities of the methanolic extracts of a Japanese lichen, *Candelariella vitellina*, and a Japanese mushroom, *Ganoderma applanatum*. *Egyptian Pharmaceutical Journal* 19(1): 67-73.
 10. Elkhateeb WA, Elnahas MO, Thomas PW, Daba GM (2019) To Heal or Not to Heal? Medicinal Mushrooms Wound Healing Capacities. *ARC Journal of Pharmaceutical Sciences* 5(4): 28-35.
 11. Elkhateeb WA, Daba GM, Elnahas MO, Thomas P (2019) Anticoagulant capacities of some medicinal mushrooms. *ARC J Pharma Sci* 5: 12-16.
 12. Elkhateeb W, Elnahas MO, Paul W, Daba GM (2020) *Fomes fomentarius* and *Polyporus squamosus* models of marvel medicinal mushrooms. *Biomed Res Rev* 3(1): 119.
 13. Elkhateeb WA, Daba GM (2021) Mycotherapy of the good and the tasty medicinal mushrooms *Lentinus*, *Pleurotus*, and *Tremella*. *Journal of Pharmaceutics and Pharmacology Research* 4(2): 1-6.
 14. Elkhateeb WA, Daba GM (2021) The Fascinating Bird's Nest Mushroom, Secondary Metabolites and Biological Activities. *International Journal of Pharma Research and Health Sciences* 9 (1): 3265-3269.
 15. Elkhateeb WA, Daba GM, Gaziea SM (2021) The Anti-Nemic Potential of Mushroom against Plant-Parasitic Nematodes. *Open Access Journal of Microbiology & Biotechnology* 6(1): 1-6.
 16. Elkhateeb WA, Elnahas MO, Thomas PW, Daba GM (2020) *Trametes Versicolor* and *Dictyophora Indusiata* Champions of Medicinal Mushrooms. *Open Access Journal of Pharmaceutical Research* 4(1): 1-7.
 17. Thomas PW, Elkhateeb WA, Daba GM (2020) *Chaga (Inonotus obliquus)*: a medical marvel but a conservation dilemma?. *Sydowia* 72: 123-130.
 18. Sharma SK, Gautam N (2017) Chemical and bioactive profiling, and biological activities of coral fungi from north-western Himalayas. *Scientific reports* 7(1): 1-13.
 19. Jais HM, Tajuddin R, Iffendy KA (2014) Macrofungi of a Healty Campus (Penerbit USM). Penerbit USM.
 20. Kuo M, Methven A (2010) 100 cool mushrooms. University of Michigan Press.
 21. Kamalakannan A, Syamala M, Sankar P, Shreedeevasena M, Ajay M (2020) Mushrooms-A Hidden Treasure. JPS Scientific, Tamil Nadu, India, pp: 1-136.
 22. Cheung PCK (2010) The nutritional and health benefits of mushrooms. *Nut Bull* 35(4): 292-299.
 23. Hobbs C (2002) Medicinal mushrooms: an exploration of tradition, healing, and culture. Book Publishing Company, pp: 1-402.
 24. Rathee S, Rathee D, Rathee D, Kumar V, Rathee P (2012) Mushrooms as therapeutic agents. *Braz J Pharmacog* 22(2): 459-474.
 25. Xu T, Beelman R (2015) The bioactive compounds in medicinal mushrooms have potential protective effects against neurodegenerative diseases. *Adv Food Technol Nut Sci* 1(2): 62-66.
 26. Halpern G (2007) Healing mushrooms. Garden City Park, New York, USA: Square One Publishers Inc., pp: 1-194.
 27. Rahi D, Malik D (2016) Diversity of mushrooms and their metabolites of nutraceutical and therapeutic significance. *J Mycol* pp: 1-19.
 28. De Silva D, Rapior S, Sudarman E, Stadler M, Jianchu X, et al. (2013) Bioactive metabolites from macrofungi: ethnopharmacology, biological activities and chemistry. *Fungal Div* 62: 1-40.
 29. Johnston PR, Whitton SR, Buchanan PK, Park D,

- Pennycook SR, et al. (2006) The basidiomycete genus *Favolaschia* in New Zealand. *New Zealand Journal of Botany* 44(1): 65-87[]]
30. Gillen K, Læssøe T, Kirschner R, Piepenbring M (2013) *Favolaschia* species Agaricales, Basidiomycota from Ecuador and Panama. *Nova Hedwigia* 96(1-2): 117-165[]]
 31. Robinson R (2013) First record of *Favolaschia calocera* in Western Australia. *Australasian Mycologist* 31: 41-43[]]
 32. Ainsworth AM, Farley D, Gainey P, Penna P, Suz LM (2015) Invasion of the orange ping-pong bats: the rapidly changing distribution of *Favolaschia calocera*. *Field Mycology* 16(4): 113-120[]]
 33. Kornsakulkarn J, Palasarn S, Choowong W, Thongpanchang T, Boonyuen N, et al. (2020) Antimalarial 9-Methoxystrobinurins, Oudemansins, and Related Polyketides from Cultures of Basidiomycete *Favolaschia* Species. *Journal of natural products* 83(4): 905-917[]]
 34. Kornsakulkarn J, Thongpanchang C, Chainoy R, Choowong W, Nithithanasilp S, et al. (2010) Bioactive metabolites from cultures of basidiomycete *Favolaschia tonkinensis*. *Journal of natural products* 73(4): 759-762.
 35. Wood KA, Kau DA, Wrigley SK, Beneyto R, Renno DV, et al. (1996) Novel β -methoxyacrylates of the 9-methoxystrobinurin and oudemansin classes produced by the basidiomycete *Favolaschia pustulosa*. *Journal of natural products* 59(7): 646-649.
 36. Engler M, Anke T, Sterner O (1998) Production of antibiotics by *Collybia nivalis*, *Omphalotus olearius*, a *Favolaschia* and a *Pterula* species on natural substrates. *Z Naturforsch C J Biosci* 53(5-6): 318-324.
 37. Anke T, Werle A, Zapf S, Velten R, Steglich W (1995) Favolon, a new antifungal triterpenoid from a *Favolaschia* species. *The Journal of antibiotics* 48(7): 725-726.
 38. Anke T, Werle A, Kappe R, Sterner O (2004) Laschiatrion, a new antifungal agent from a *Favolaschia* species (Basidiomycetes) active against human pathogens. *The Journal of antibiotics* 57(8): 496-501[]]
 39. Minter DW, Cannon PF, Peredo HL (1987) South American species of *Cyttaria*: (A remarkable and beautiful group of edible ascomycetes). *Mycologist* 1(1): 7-11[]]
 40. Crisci JV, Gamundi IJ, Cabello MN (1988) A cladistic analysis of the genus *Cyttaria* (Fungi-Ascomycotina). *Cladistics* 4(3): 279-290[]]
 41. Zeng X, Suwandi J, Fuller J, Doronila A, Ng K (2012) Antioxidant capacity and mineral contents of edible wild Australian mushrooms. *Food Science and Technology International* 18(4): 367-379[]]
 42. Toledo CV, Barroetaveña C, Fernandes Â, Barros L, Ferreira IC (2016) Chemical and antioxidant properties of wild edible mushrooms from native *Nothofagus* spp. forest, Argentina. *Molecules* 21(9): 1201[]]
 43. Leiva-Portilla DJ, Rodríguez-Núñez KE, Rodríguez-Ramos FJ, Delgadillo Acevedo Á, Uribe E (2020) Impact on Physicochemical Composition and Antioxidant Activity of the Wild Edible Mushroom *Cyttaria espinosae* Subjected to Drying. *Chemistry & Biodiversity* 17(11): e2000642[]]
 44. Jacinto-Azevedo B, Valderrama N, Henríquez K, Aranda M, Aqueveque P (2021) Nutritional value and biological properties of Chilean wild and commercial edible mushrooms. *Food Chemistry* 356: 129651.

